Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2004 02:08 ET | Source: Crucell N.V.

Crucell and DSM Announce PER.C6 Licensing Agreement with GlaxoSmithKline for Monoclonal Antibody Production

LEIDEN, The Netherlands, Aug. 13, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that...
July 09, 2004 04:41 ET | Source: Crucell N.V.

Crucell Announces Second Quarter 2004 Results

LEIDEN, The Netherlands, July 9, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) today announced its financial results for the second quarter of 2004....
July 07, 2004 02:16 ET | Source: Crucell N.V.

Crucell -- DSM Biologics Alliance Announces Development Milestone Achievement

LEIDEN/SITTARD, The Netherlands, July 7, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today the...
July 06, 2004 02:14 ET | Source: Crucell N.V.

GlaxoSmithKline Renews PER.C6(R) License Agreement with Crucell

LEIDEN, The Netherlands, July 6, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that GlaxoSmithKline has decided to renew its PER.C6(R)...
June 25, 2004 02:08 ET | Source: Crucell N.V.

Crucell Discovers Human Monoclonal Antibody that Protects Against SARS

LEIDEN, The Netherlands, June 25, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today the discovery of an antibody for protection against SARS...
June 15, 2004 02:12 ET | Source: Crucell N.V.

Crucell and DSM Announce PER.C6(R) Licensing Agreement with Chiron for Monoclonal Antibody Production

LEIDEN/SITTARD, The Netherlands, June 15, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today...
June 10, 2004 02:10 ET | Source: Crucell N.V.

Crucell and DSM Announce PER.C6(R) Licensing Agreement with Merus for Production of Monoclonal Antibody Combinations

LEIDEN/SITTARD, The Netherlands, June 10, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today...
June 09, 2004 08:15 ET | Source: Crucell N.V.

Crucell to Present at Needham & Company Third Annual Biotechnology Conference, June 16

LEIDEN, Netherlands, June 9, 2004 (PRIMEZONE) -- Crucell N.V. (Nasdaq:CRXL) has announced its Chief Financial Officer, Leonard Kruimer, will present at the Annual Needham & Company Biotechnology...
June 08, 2004 02:19 ET | Source: Crucell N.V.

Crucell and DSM Announce PER.C6(R) Licensing Agreement with PanGenetics for Monoclonal Antibody Production

LEIDEN/SITTARD, The Netherlands, June 8, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that...
June 03, 2004 08:13 ET | Source: Crucell N.V.

Market authorization for PER.C6(R)-based West Nile virus veterinary vaccine in Israel

LEIDEN, The Netherlands, June 3, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) has announced market authorization for a West Nile virus veterinary vaccine...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right